Therapeutic targeting of Syk in autoimmune diabetes

Area of Science:

• Immunology
• Endocrinology
• Pharmacology

Background:

• Spleen tyrosine kinase (Syk) is essential for signaling pathways in antigen-presenting cells (APCs) mediated by immunoreceptors like the B cell receptor (BCR) and Fc receptor (FcR).
• Dysregulation of immune responses involving APCs contributes to the pathogenesis of T cell-mediated autoimmune diseases, including type 1 diabetes.

Purpose of the Study:

• To investigate the role of Syk in APCs in the context of T cell-mediated autoimmunity, specifically type 1 diabetes.
• To evaluate the therapeutic potential of a selective Syk inhibitor, R788, in preclinical models of type 1 diabetes.

Main Methods:

• Conditional ablation of the syk gene in dendritic cells (DCs) of RIP-mOVA mice.
• Pharmacological inhibition of Syk using R788 in wild-type RIP-mOVA mice and non-obese diabetic (NOD) mice.
• Assessment of immune cell populations (DCs, B cells), T cell priming, autoantibody production, and diabetes onset/progression.

Main Results:

• Conditional Syk ablation in DCs abrogated FcgammaR-mediated T cell priming.
• R788 treatment blocked both FcgammaR and BCR-mediated antigen presentation, delaying diabetes onset and progression in NOD mice.
• R788 reduced DC and B cell numbers, decreased insulin-specific CD8+ T cell priming, and lowered total Ig concentrations.
• Interestingly, R788 treatment increased the proportion of IL-10-producing B cells, suggesting the induction of a tolerogenic immune environment.

Conclusions:

• Syk in APCs plays a critical role in initiating and perpetuating T cell-mediated autoimmune responses relevant to type 1 diabetes.
• Pharmacological inhibition of Syk represents a promising therapeutic strategy for managing T cell-mediated autoimmune diseases like type 1 diabetes.
• Syk inhibition modulates both innate and adaptive immune responses, leading to immune tolerance.